Marshall Wace
CTXR icon

Marshall Wace’s Citius Pharmaceuticals CTXR Stock Holding History

Marshall Wace’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,038
Closed -$40.3K – 2740
2022
Q4 		$40.3K Buy
+2,038
New +$55.6K ﹤0.01% 2845
2021
Q2 		– Sell
-2,755
Closed -$123K – 2718
2021
Q1 		$123K Buy
+2,755
New +$110K ﹤0.01% 2337

Other funds holding CTXR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Marshall Wace's CTXR Position: Q1 2023 in Review

Marshall Wace sold out of Citius Pharmaceuticals (CTXR) in Q1 2023, closing a stake of 2,038 shares — an estimated $40.3K sold.

Marshall Wace first reported a position in CTXR in Q1 2021 and held it in 2 quarters. The position peaked at $123K in Q1 2021. 55 funds tracked by Wall St. Rank hold CTXR as of Q1 2023.

  • Marshall Wace reported no remaining Citius Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Marshall Wace sold 2,038 Citius Pharmaceuticals shares in Q1 2023, an estimated $40.3K.
  • Marshall Wace first reported a position in Citius Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Marshall Wace's Citius Pharmaceuticals position peaked at $123K in Q1 2021.
  • 55 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2023.

Based on Marshall Wace's 13F filing for Q1 2023, filed 15 May 2023.